-
Mashup Score: 20Closed Borders of our Empathy — Critical Forced Displacement - 2 day(s) ago
Dr. Alina Sadaf, MD recounts her experiences as a pediatric oncologist working with Afghan refugees in Lahore, Pakistan.
Categories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Dietary interventions in cancer: a systematic review of all randomized controlled trials - 5 day(s) ago
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Source: academic.oup.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Dietary interventions in cancer: a systematic review of all randomized controlled trials - 8 day(s) ago
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Source: academic.oup.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 40
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.
Source: podcasters.spotify.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 46
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution adds value to the interpretation of AE data.Patients in the placebo arm of two …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial - 11 day(s) ago
Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.To determine whether zoledronic acid administered …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 69In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease - 11 day(s) ago
Blood Cancer Journal – In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 46
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution adds value to the interpretation of AE data.Patients in the placebo arm of two …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 36Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis - PubMed - 17 day(s) ago
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
Such a beautiful and poignant piece by my medical school classmate, Dr Alina Sadaf, on caring for Afghan children with cancer in Pakistan. 😢 https://t.co/uEYIokrmNf